Digg
Del.icio.us
Yahoo
Google
Newsvine
Sarah Cannon Research Institute To Present Clinical Trial Findings At International Conference For Oncology Drug Development
November 12, 2011
NASHVILLE, TN, Nov. 12, 2011 – Sarah Cannon Research Institute (SCRI) investigators will present the findings of several important cancer trials during the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications, November 12-16, in San Francisco. Conference organizers include the European Organisation for the Research and Treatment of Cancer, the U.S. National Cancer Institute and the American Association for Cancer Research.
This meeting provides a platform to present recent advances in the early development of promising new compounds. SCRI researchers have primary or co-author roles on eight poster presentations that focus on novel drugs and treatment combinations for solid tumors and advanced cancer.
“This symposium is a distinguished international conference for researchers to discuss early-phase trials in the treatment of cancer patients,” said Howard A. “Skip” Burris III, M.D., SCRI’s chief medical officer and executive director of drug development. “The number of SCRI abstracts accepted for presentation reflects the quality of innovative research in which our drug development team is participating.”
Jeffrey R. Infante, M.D., SCRI’s director of drug development, will present data as lead author on a phase I study of the MEK inhibitor GSK1120212 plus everolimus in patients with advanced solid tumors on Monday, November 14, from 12:30-2:30pm PT. SCRI study co-authors from SCRI include Dr. Burris, Johanna Bendell, M.D., SCRI’s director of GI cancer research and Suzanne Jones, Pharm.D., SCRI’s scientific director, drug development.
Dr. Bendell is the first author of a phase I dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumors that will be presented Monday, November 14, from 12:30-2:30pm PT. Dr. Jones co-authored this study.
SCRI investigators co-authored six additional research posters that will be presented during the symposium:
|
Presentation Title: |
SCRI Study Co-Authors |
Presentation Time: |
|
First-in-patient study of PF-05212384, a small-molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: update on safety, efficacy and pharmacology |
Dr. Johanna Bendell |
Sunday, November 13, 12:30-2:30pm PT |
|
Phase I dose-escalation study of selumetinib in combination with docetaxel in patients with advanced solid tumors |
Dr. Howard Burris Dr. Jeffrey Infante |
Monday, November 14, 12:30-2:30pm PT |
|
A phase I, open-label, dose escalation, non-randomized study to assess the maximum tolerated dose, dose limiting toxicity and pharmacokinetics of OPB-31121 in subjects with advanced solid tumors |
Dr. Johanna Bendell Dr. Suzanne Jones |
Monday, November 14, 12:30-2:30pm PT |
|
A Phase I study of the MEK inhibitor GSK1120212 (GSK212) in combination with PI3K/mTOR inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors |
Dr. Jeffrey Infante |
Monday, November 14, 12:30-2:30pm PT |
|
Phase Ib relative bioavailability study of enteric-coated tablet in reference to powder-in-capsule formulation of the investigational drug alisertib (MLN8237), an aurora A kinase inhibitor, in patients with advanced non-hematologic malignancies |
Dr. Howard Burris Dr. Jeffrey Infante |
Tuesday, November 15, 12:30-2:30pm PT |
|
A phase I QTc study of tivozanib in patients with advanced solid tumors |
Dr. Jeffrey Infante |
Tuesday, November 15, 12:30-2:30pm PT |
About the EORTC-NCI-AACR Symposium
This major conference brings together over 3,000 academics, scientists, and representatives from the pharmaceutical industry to discuss innovations in drug development, target selection and the impact of new discoveries in molecular biology. During the last few years, numerous innovative agents have been discovered as a result of tremendous developments in the understanding of the molecular basis of cancer. Further clinical progress in cancer treatment will be accomplished mainly through the conduct of translational research projects, efficient new drug development and the execution of large, prospective, randomized, multicenter cancer clinical trials. Together, the level of excitement surrounding targeted therapy and the high caliber of the science presented fuel the power of this meeting to attract the world’s leaders in the development of new cancer therapeutics.
About SCRI
Sarah Cannon Research Institute (SCRI) is a global strategic research organization focusing on advancing therapies and accelerating drug development. It is one of the largest clinical research programs, conducting community-based clinical trials in oncology, cardiology, gastroenterology and other therapeutic areas through affiliations with a network of more than 700 physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites. For more information, please visit sarahcannonresearch.com or follow us on Twitter or Facebook.
Our News
View All News-
SCRI in the News
April 12, 2012
-
Nashville woman's cancer fight inspiring thousands
March 26, 2012
NASHVILLE, TN (WSMV) - Her's was a bleak situation. A young Nashville mom's third child was stillborn, then, to make matters worse, the woman was diagnosed with stage four colon cancer.
-
Collaborating to Provide Comprehensive Cancer Care
March 22, 2012
A discussion between primary care providers and the oncology multidisciplinary team” event - also known as Oncology 101. The event is a CME program for Primary Care Physicians and advanced practitioners to learn more about oncology care.